Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications

Abstract

Numerous drugs have emerged to treat various diseases, such as COVID-19, cancer, and protect human health. Approximately 40% of them are lipophilic and are used for treating diseases through various delivery routes, including skin absorption, oral administration, and injection. However, as lipophilic drugs have a low solubility in the human body, drug delivery systems (DDSs) are being actively developed to increase drug bioavailability. Liposomes, micro-sponges, and polymer-based nanoparticles have been proposed as DDS carriers for lipophilic drugs. However, their instability, cytotoxicity, and lack of targeting ability limit their commercialization. Lipid nanoparticles (LNPs) have fewer side effects, excellent biocompatibility, and high physical stability. LNPs are considered efficient vehicles of lipophilic drugs owing to their lipid-based internal structure. In addition, recent LNP studies suggest that the bioavailability of LNP can be increased through surface modifications, such as PEGylation, chitosan, and surfactant protein coating. Thus, their combinations have an abundant utilization potential in the fields of DDSs for carrying lipophilic drugs. In this review, the functions and efficiencies of various types of LNPs and surface modifications developed to optimize lipophilic drug delivery are discussed.

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

“…Lipids, also known as fats, constitute a group of compounds with diverse structures but similar physicochemical properties. They are insoluble in water but readily dissolve in organic solvents [43]. Lipids are categorized into several main groups, including simple fats, encompassing true fats (glycerol esters and higher fatty acids) and waxes (esters of higher monohydroxy alcohols and higher fatty acids).…”

Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up

“…Further, SLNs face challenges due to their tendency of a high initial drug release and leakage during storage, attributed to solid lipid crystallization after the synthesis cooling process. PEGylation is a surface modification strategy for LNPs that could enhance the release rate by decreasing the surface tension of nanoparticles [ 91 , 92 ]. A substantial challenge in LNPs studies is the potential for burst release with the system.…”

Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases

“…A dual-targeted delivery system is capable of accumulating outside the cell and penetrating inside the cell to enhance the delivery of genes to target cells. Despite the many advantages of liposomes as nucleic acid carriers, the production process of preparation and nucleic acid encapsulation requires the use of organic solvent injection, which makes the production process complicated and limits the large-scale production of liposomes by their limited physical stability, low drug loading capacity, and the possibility of drug leakage ( Mendes et al, 2022 ; Seo et al, 2023 ).…”